Summary
Johnson & Johnson (JNJ) filed an 8-K on July 17, 2024, primarily to disclose its financial results for the second quarter ended June 30, 2024. The filing includes a press release and supplementary sales data, offering investors a look into the company's operational performance and financial condition during the period. Investors should review the attached exhibits for detailed sales figures and earnings statements to understand the company's revenue generation and profitability trends.
Key Highlights
- 1JNJ announced its second quarter 2024 sales and earnings on July 17, 2024.
- 2The 8-K filing's primary purpose is to report the company's financial performance for the quarter ended June 30, 2024.
- 3Key financial information is contained within the attached press release (Exhibit 99.1).
- 4Investors can find unaudited comparative supplementary sales data and condensed consolidated statements of earnings in Exhibit 99.2.
- 5The filing provides a snapshot of JNJ's financial condition and results of operations for the specified period.
- 6No other significant operational or strategic updates were detailed in this specific 8-K filing beyond the Q2 2024 financial results.